Role of adjuvant chemotherapy in the management of non-granulosa cell ovarian sex cord-stromal tumors

• Published in: Journal of gynecologic oncology Vol. 30; no. 2; pp. 1 - 9
• Main Authors: Dimitrios Nasioudis, Theofano Orfanelli, Melissa K Frey, Eloise Chapman-davis, Thomas A Caputo, Steven S Witkin, Kevin Holcomb
• Format: Journal Article
• Language: Korean
• Published: 대한부인종양학회 01.03.2019
• Subjects: Chemotherapy; Ovarian Cancer; Sex Cord-stromal Tumor
• ISSN: 2005-0380

Objective: To investigate the role of adjuvant chemotherapy (CT) in the management of ovarian non-granulosa cell (GC) sex cord-stromal tumors (SCSTs). Methods: The National Cancer Database was accessed and patients diagnosed between 2004 and 2013 with a malignant non-GC SCST were selected. Overall survival (OS) was evaluated with Kaplan-Meier curves and compared with the log-rank test. Multivariate survival analysis was performed with Cox regression. Factors associated with the administration of CT were evaluated with the chi-square test and binary logistic regression. Results: A total of 391 patients were identified. The majority had a Sertoli-Leydig cell tumor (SLCT) (73.2%) and early stage disease (84.8%). A total of 203 (51.9%) patients received CT. Advanced disease stage, younger age, high-grade histology, White race, large tumor size and SLCT histology were associated with administration of CT. For patients with early stage disease, there was no difference in OS between those who did (n=134) and did not receive CT (n=157), p=0.40; 5-year OS rates were 81.7% and 84.6%, respectively. No mortality benefit was observed (hazard ratio=0.73; 95% confidence interval=0.38-1.4) after controlling for tumor histology. Median OS of women with advanced stage disease who received CT (n=41) was 34.96 months compared to 15.51 months for those who did not (n=11), p=0.013. Conclusion: Adjuvant CT was associated with improved survival for patients with advanced stage non-GC SCSTs. No clear benefit was found for those with early stage disease.